KALEXATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for KALEXATE (KALEXATE).
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
| Metabolism | KALEXATE is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways are involved. |
| Excretion | Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%) |
| Half-life | 12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases) |
| Protein binding | 60-70% primarily to albumin |
| Volume of Distribution | 1.2-1.6 L/kg; indicates extensive extravascular distribution |
| Bioavailability | Oral: 85-95% |
| Onset of Action | Oral: 1-2 hours; IV: within 5-10 minutes |
| Duration of Action | Oral: 12-24 hours; IV: 6-12 hours; dosing interval adjusted based on renal function |
| Molecular Weight | 362.37 |
10 mg orally once daily.
| Dosage form | POWDER |
| Renal impairment | GFR >= 60 mL/min: no adjustment; GFR < 60 mL/min: use not recommended. |
| Liver impairment | Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No specific dose adjustment; monitor renal function. |
| 1st trimester | Avoid due to risk of fetal harm based on animal studies; consider alternative therapy. |
| 2nd trimester | Use only if benefit outweighs risk; monitor fetal growth and amniotic fluid volume. |
| 3rd trimester | Avoid due to risk of neonatal renal impairment or oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for KALEXATE (KALEXATE).
| Placental transfer | Crosses placenta extensively; fetal concentrations similar to maternal levels. |
| Breastfeeding | Not recommended during breastfeeding due to potential adverse effects in the infant; consider discontinuing drug or breastfeeding. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypernatremia) may indirectly affect fetal development. No specific teratogenic risk is documented; avoid severe maternal electrolyte imbalances. |
| Fetal Monitoring | Monitor maternal serum potassium, sodium, calcium, bicarbonate, and acid-base status regularly. Assess for signs of electrolyte imbalance in mother and symptoms in fetus (e.g., fetal arrhythmias from hypokalemia). |
| Fertility Effects | No known direct effects on fertility. Indirect effects from electrolyte disturbances may impact reproductive function, but no specific data available. |
■ FDA Black Box Warning
Risk of serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be screened for latent tuberculosis prior to initiation. If serious infection develops, interrupt KALEXATE until infection is controlled.
| Serious Effects |
Hypersensitivity to Kalexate or any componentSevere renal impairment (eGFR < 30 mL/min/1.73 m²)
| Precautions | Serious infections, Hepatotoxicity (elevated liver enzymes), Neutropenia, Thrombocytopenia, Lipid elevations, Gastrointestinal perforation (risk higher in patients with diverticulitis), Hypersensitivity reactions, Live vaccines should not be given concurrently |
| Food/Dietary | Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes). Do not mix with fruit juices containing high potassium (e.g., orange, tomato). Maintain adequate fluid intake to prevent constipation. |
| Clinical Pearls | Kalexate (sodium polystyrene sulfonate) exchanges sodium for potassium in the gastrointestinal tract. Onset of action is 2-12 hours. Avoid in patients with hypokalemia, severe hypernatremia, or bowel obstruction. Monitor serum potassium and sodium levels regularly. Use with caution in patients with congestive heart failure or severe edema due to sodium load. Administer orally or as a retention enema; do not mix with fruit juices containing high potassium (e.g., orange juice). |
| Patient Advice | Take this medication exactly as prescribed to lower high potassium levels. · Do not mix with orange juice or other high-potassium beverages. · Drink plenty of water with each dose to prevent constipation. · Report any signs of bowel obstruction (severe abdominal pain, vomiting, no bowel movements) immediately. · Notify your doctor if you experience irregular heartbeat, muscle weakness, or numbness/tingling. · This medication contains sodium; inform your doctor if you have heart failure or high blood pressure. |
Loading safety data…